Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (Stat ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2019 Earnings Conference Call August 1, 2019 8:30 AM ET Company Participants Shari Annes - IR Rachel King - President, CEO & Director Brian Hahn - SVP, CFO & Secretary Helen Thackray - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Subhalaxmi Nambi - Cowen and Company Peter Lawson - SunTrust Robinson Humphrey Danielle Brill - Piper Jaffray Companies Stephen Willey - Stifel, Nicolaus & Company Biren Amin - Jefferies Edward White - H.C. Wain ...

(Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended June 30, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Shari Annes - IR Rachel King - President, CEO & Director Brian Hahn - SVP, CFO & Secretary Helen Thackray - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Edward White - H.C. Wainwright & Co. Irina Margine - Cowen and Company Biren Amin - Jefferies Operator Good morning, and thank you all for joining GlycoMimetics First Quarter 2019 Conference Call. [Operator Instruc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

GlycoMimetics (NASDAQ:GLYC) Q4 2018 Earnings Conference Call March 6, 2019 8:30 AM ET Company Participants Shari Annes - IR, Annes Associates Rachel King - CEO Brian Hahn - CFO Helen Thackray - SVP, Development & CMO Conference Call Participants Jotin Marango - ROTH Capital Stephen Wiley - Stifel Peter Lawson - SunTrust Robinson Biren Amin - Jefferies Operator Good morning and thank you all for joining the GlycoMimetics call. At this time, all participants are in listen-only mode. Following management's rem ...

Commission file number 001-36177 GlycoMimetics, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 9708 Medical Center Drive Rockville, Maryland 20850 (Addre ...